1271700
USP
Fluconazol
United States Pharmacopeia (USP) Reference Standard
Synonym(e):
Fluconazol, 2-(2,4-Difluorphenyl)-1,3-bis-(1H-1,2,4-triazol-1-yl)-propan-2-ol
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
Empirische Formel (Hill-System):
C13H12F2N6O
CAS-Nummer:
Molekulargewicht:
306.27
MDL-Nummer:
UNSPSC-Code:
41116107
PubChem Substanz-ID:
NACRES:
NA.24
Empfohlene Produkte
Qualität
pharmaceutical primary standard
API-Familie
fluconazole
Hersteller/Markenname
USP
Anwendung(en)
pharmaceutical (small molecule)
Format
neat
SMILES String
FC1=CC(F)=C(C(CN2N=CN=C2)(O)CN3N=CN=C3)C=C1
InChI
1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2
InChIKey
RFHAOTPXVQNOHP-UHFFFAOYSA-N
Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich
Allgemeine Beschreibung
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Anwendung
- Enhanced antifungal activity of fluconazole: A study optimized fluconazole-embedded transfersomal gel, demonstrating improved antifungal activity and compatibility. This research is crucial for enhancing fluconazole′s efficacy against resistant fungal strains, making it a pivotal tool in the fight against fungal infections (Cheng et al., 2024).
- Antifungal mechanisms against drug-resistant strains: Research on the antifungal activity of a trypsin inhibitor from chia seeds against fluconazole-resistant Candida species assessed its potential as a novel therapeutic approach. This study contributes valuable insights into natural compounds enhancing fluconazole′s effectiveness, crucial for developing alternative antifungal therapies (Nogueira et al., 2024).
- Advancements in fungal pathogenesis: The isolation and identification of Wickerhamiella tropicalis from blood culture using MALDI-MS highlight innovative diagnostic techniques that enhance the understanding of fungal pathogenesis. This research is essential for advancing microbial diagnostics and tailoring treatments to combat invasive fungal infections effectively (Takei et al., 2024).
Biochem./physiol. Wirkung
Fluconazol ist ein ein antifungales Mittel. Es ist hoch selektiver Inhibitor von fungaler Cytochrom P-450 C-14 Sterol α-Demethylierung. Fluconazol ist ein potenter Inhibitor von CYP2C9. Fluconazol beeinträchtigt die fungale Ergosterolsynthese und reguliert das Metallothionein-Gen herunter.
Hinweis zur Analyse
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Sonstige Hinweise
Sales restrictions may apply.
Ähnliches Produkt
Produkt-Nr.
Beschreibung
Preisangaben
Signalwort
Danger
H-Sätze
Gefahreneinstufungen
Acute Tox. 4 Oral - Aquatic Chronic 3 - Lact. - Repr. 1B
Lagerklassenschlüssel
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Kunden haben sich ebenfalls angesehen
Wei Zhao et al.
Clinical pharmacokinetics, 53(11), 1005-1018 (2014-08-27)
Selection of the first-dose-in-neonates is challenging. The objective of this proof-of-concept study was to evaluate a pharmacokinetic bridging approach to predict a neonatal dosing regimen. We selected fluconazole as a paradigm compound. We used data from studies in juvenile mice
Kim C M van der Elst et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 59(11), 1527-1533 (2014-08-26)
Fluconazole is recommended as first-line treatment in invasive candidiasis in children and infants. Although timely achievement of adequate exposure of fluconazole improves outcome, therapeutic drug monitoring is currently not recommended. We conducted a retrospective study of critically ill children treated
M C Ethier et al.
British journal of cancer, 106(10), 1626-1637 (2012-05-10)
Objectives were to compare systemic mould-active vs fluconazole prophylaxis in cancer patients receiving chemotherapy or haematopoietic stem cell transplantation (HSCT). We searched OVID MEDLINE and the Cochrane Central Register of Controlled Trials (1948-August 2011) and EMBASE (1980-August 2011). Randomised controlled
Jenny Wan Sai Cheong et al.
Medical mycology, 51(3), 261-269 (2012-09-20)
With the widespread use of long-term fluconazole prophylaxis and suppressive treatment, the potential development of fluconazole resistance poses a threat to the management of cryptococcal disease. Interpretive breakpoints for the in vitro antifungal susceptibility testing of C. neoformans have not
Daniel K Benjamin et al.
JAMA, 311(17), 1742-1749 (2014-05-06)
Invasive candidiasis in premature infants causes death and neurodevelopmental impairment. Fluconazole prophylaxis reduces candidiasis, but its effect on mortality and the safety of fluconazole are unknown. To evaluate the efficacy and safety of fluconazole in preventing death or invasive candidiasis
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.